Kimberley Botting-Lawford
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kimberley Botting-Lawford has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Dino A. Giussani
Department of Physiology, Development and Neuroscience University of Cambridge Cambridge UK
7 shared publications - Janna Leigh Morrison
University of South Australia
4 shared publications - Beth Joyce Allison
The Ritchie Centre, Hudson Institute of Medical Research, Clayton, Australia
3 shared publications - Michael P. Murphy
MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
3 shared publications - Youguo Niu
Department of Physiology, Development and Neuroscience University of Cambridge Cambridge UK
3 shared publications - Anna Louise David
University College London
2 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Springer Nature in Research Square
Human antenatal corticosteroid therapy independent of preterm birth programmes cardiac dysfunction and fibrosis in ovine adult offspring
Antenatal corticosteroids (ACS) are widely administered to women at risk of preterm birth, yet their independent contribution to long-term cardiovascular risk remains unresolved. Using a term-born ovine model that separates ACS exposure from prematurity, we mapped cardiovascular responses from fetal life to adolescence following a clinically relevant dexamethasone regimen. ACS triggered acute fetal vasoconstriction and vascular remodelling, followed by the emergence of systolic and diastolic cardiac dysfunction by term. These effects persisted into adolescence, manifesting as impaired cardiac contractile function, restrictive ventricular filling and increased myocardial fibrosis, despite preserved resting blood pressure. By isolating the effects of ACS from those of preterm birth, here we show that fetal glucocorticoid exposure is a direct driver of adverse cardiovascular programming. These findings reveal a previously unresolved mechanism linking a global perinatal intervention to long-term cardiac remodelling, thereby having important implications for understanding cardiovascular risk in individuals exposed to ACS before birth.
- 8 October 2026
- Published by Springer Nature in Research Square
Open AccessHuman antenatal corticosteroid therapy independent of preterm birth programmes cardiac dysfunction and fibrosis in ovine adult offspring
Antenatal corticosteroids (ACS) are widely administered to women at risk of preterm birth, yet their independent contribution to long-term cardiovascular risk remains unresolved. Using a term-born ovine model that separates ACS exposure from prematurity, we mapped cardiovascular responses from fetal life to adolescence following a clinically relevant dexamethasone regimen. ACS triggered acute fetal vasoconstriction and vascular remodelling, followed by the emergence of systolic and diastolic cardiac dysfunction by term. These effects persisted into adolescence, manifesting as impaired cardiac contractile function, restrictive ventricular filling and increased myocardial fibrosis, despite preserved resting blood pressure. By isolating the effects of ACS from those of preterm birth, here we show that fetal glucocorticoid exposure is a direct driver of adverse cardiovascular programming. These findings reveal a previously unresolved mechanism linking a global perinatal intervention to long-term cardiac remodelling, thereby having important implications for understanding cardiovascular risk in individuals exposed to ACS before birth.
- Open Access
- 21 August 2025
- Published by The Royal Society in Philosophical Transactions of the Royal Society B: Biological Sciences
- Vol. 380 (1933) , 20240183
Antioxidants: powering the fight against fetal hypoxia
Hypoxia is a common challenge in fetal development. Short-term acute episodes occur during labour owing to uterine contractions or umbilical cord compression. In response, the fetus prioritizes oxygen and nutrient delivery to the brain, heart and adrenal glands at the expense of other organs, a mechanism known as the fetal brain-sparing response. However, prolonged fetal hypoxia can occur in many conditions, including placental insufficiency, pre-eclampsia, high-altitude pregnancy and fetal congenital heart disease. Chronic hypoxia increases placental and fetal oxidative stress, triggering increased long-term cardiovascular risks in adult offspring, including hypertension and coronary artery disease. Antioxidants could potentially prevent this. However, as reactive oxygen species play a crucial role in the fetal brain-sparing response, excessive antioxidant use could weaken fetal defences against acute hypoxia, increasing the risk of hypoxic–ischaemic encephalopathy. Thus, for clinical use, an antioxidant should protect against programmed cardiovascular disease while preserving fetal brain sparing. This review summarizes preclinical evidence on the efficacy of antioxidants in preventing cardiovascular disease in the offspring of hypoxic pregnancy. We compare their effects on fetal brain sparing, highlighting the ability of the mitochondria-targeted antioxidant MitoQ to protect against programmed cardiovascular disease while preserving fetal brain sparing and outlining steps for clinical translation. This article is part of the discussion meeting issue ‘Pregnancy at high altitude: the challenge of hypoxia’.
- 21 August 2025
- Published by The Royal Society in Philosophical Transactions of the Royal Society B: Biological Sciences
- Vol. 380 (1933) , 20240183
Open AccessAntioxidants: powering the fight against fetal hypoxia
Hypoxia is a common challenge in fetal development. Short-term acute episodes occur during labour owing to uterine contractions or umbilical cord compression. In response, the fetus prioritizes oxygen and nutrient delivery to the brain, heart and adrenal glands at the expense of other organs, a mechanism known as the fetal brain-sparing response. However, prolonged fetal hypoxia can occur in many conditions, including placental insufficiency, pre-eclampsia, high-altitude pregnancy and fetal congenital heart disease. Chronic hypoxia increases placental and fetal oxidative stress, triggering increased long-term cardiovascular risks in adult offspring, including hypertension and coronary artery disease. Antioxidants could potentially prevent this. However, as reactive oxygen species play a crucial role in the fetal brain-sparing response, excessive antioxidant use could weaken fetal defences against acute hypoxia, increasing the risk of hypoxic–ischaemic encephalopathy. Thus, for clinical use, an antioxidant should protect against programmed cardiovascular disease while preserving fetal brain sparing. This review summarizes preclinical evidence on the efficacy of antioxidants in preventing cardiovascular disease in the offspring of hypoxic pregnancy. We compare their effects on fetal brain sparing, highlighting the ability of the mitochondria-targeted antioxidant MitoQ to protect against programmed cardiovascular disease while preserving fetal brain sparing and outlining steps for clinical translation. This article is part of the discussion meeting issue ‘Pregnancy at high altitude: the challenge of hypoxia’.
- Open Access
- 18 August 2025
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 66 (4) , 486-498
Translatable in‐vivo investigation of effects of progressive hypoxia in pregnancy on fetal cardiac structure and function in sheep
Objective: Human fetal growth restriction (FGR) is associated with cardiac dysfunction. However, it remains unclear whether alterations in the fetal heart in human pregnancy affected by FGR are a consequence of chronic fetal hypoxia. In this study, we used novel in‐vivo ultrasound imaging modalities in pregnant sheep to evaluate fetal cardiac responses to progressive hypoxia in late gestation. Methods: This was a prospective study of data collected between July 2019 and March 2022 from 42 Welsh mountain ewes, each carrying a single fetus. Seventeen ewes were exposed to hypoxia in isobaric chambers (10% oxygen (O 2 )) from 105 days of gestational age (dGA; with term being approximately 147 days) for 11 ± 1 days (H1, n = 5), 17 ± 1 days (H2, n = 6) or 32 ± 2 days (H3, n = 6). An ultrasound system with vendor‐specific software was used to determine fetal left ventricular (LV) and right ventricular (RV) geometry and function. Outcomes were compared with the remaining 25 gestational age‐matched ovine normoxic control pregnancies at 117 ± 1 (N1, n = 13), 124 ± 1 (N2, n = 5) and 133 ± 3 (N3, n = 7) dGA. Results: Compared to controls with expected fetal RV dominance in late gestation, hypoxic fetal sheep showed LV dominance with increasing duration of hypoxia, including statistically significant increases in mean ± SD LV/RV end‐diastolic area ratio (N1, 1.1 ± 0.2 vs H1, 1.3 ± 0.1; N2, 1.2 ± 0.4 vs H2, 1.7 ± 0.5; N3, 0.9 ± 0.1 vs H3, 1.4 ± 0.2), LV sphericity index (N3, 0.44 ± 0.04 vs H3, 0.54 ± 0.11) and LV/RV cardiac output ratio (N1, 0.55 ± 0.18 vs H1, 1.00 ± 0.31; N2, 0.80 ± 0.10 vs H2, 1.62 ± 0.59; N3, 0.74 ± 0.23 vs H3, 1.50 ± 0.58). The mean ± SD LV myocardial performance index was significantly greater in the hypoxic groups, signifying global myocardial dysfunction (N1, 0.45 ± 0.07 vs H1, 0.64 ± 0.07; N2, 0.40 ± 0.05 vs H2, 0.66 ± 0.07; N3, 0.36 ± 0.07 vs H3, 0.60 ± 0.10). While LV apical radial strain and LV apical systolic rotation were initially increased after 17 days of hypoxia, these indices were significantly reduced after 32 days of hypoxia (median LV apical radial strain: N1, 27% (interquartile range (IQR), 26–28%) vs H1, 24% (IQR, 21–26%); N2, 24% (IQR, 22–25%) vs H2, 70% (IQR, 66–79%); N3, 51% (IQR, 48–54%) vs H3, 29% (IQR, 27–32%); mean ± SD LV apical systolic rotation: N1, 7 ± 5° vs H1, 5 ± 3°; N2, 9 ± 1° vs H2, 14 ± 2°; N3, 15 ± 2° vs H3, 7 ± 2°). Hypoxic fetuses showed biventricular hypertrophy and evidence of biventricular diastolic dysfunction, with significant LV impairment presenting after 11 days of hypoxia (mean ± SD LV isovolumetric relaxation time (IVRT′) normalized by cardiac cycle (cc) length: N1, 0.10 ± 0.02 ms vs H1, 0.15 ± 0.02 ms; N2, 0.09 ± 0.01 ms vs H2, 0.14 ± 0.02 ms; N3, 0.08 ± 0.03 ms vs H3, 0.12 ± 0.02 ms), preceding RV impairment after 32 days of chronic hypoxia (mean ± SD RV‐IVRT′ normalized by cc length: N3, 0.08 ± 0.03 ms vs H3, 0.14 ± 0.03 ms). Conclusions: Progressive fetal hypoxia in sheep leads to profound changes in fetal cardiac structure and function, resulting from a switch to LV dominance triggered by fetal brain sparing. The findings also indicate that fetal cardiac compensatory reserves become exhausted with progressive hypoxia. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
- 18 August 2025
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 66 (4) , 486-498
Open AccessTranslatable in‐vivo investigation of effects of progressive hypoxia in pregnancy on fetal cardiac structure and function in sheep
Objective: Human fetal growth restriction (FGR) is associated with cardiac dysfunction. However, it remains unclear whether alterations in the fetal heart in human pregnancy affected by FGR are a consequence of chronic fetal hypoxia. In this study, we used novel in‐vivo ultrasound imaging modalities in pregnant sheep to evaluate fetal cardiac responses to progressive hypoxia in late gestation. Methods: This was a prospective study of data collected between July 2019 and March 2022 from 42 Welsh mountain ewes, each carrying a single fetus. Seventeen ewes were exposed to hypoxia in isobaric chambers (10% oxygen (O 2 )) from 105 days of gestational age (dGA; with term being approximately 147 days) for 11 ± 1 days (H1, n = 5), 17 ± 1 days (H2, n = 6) or 32 ± 2 days (H3, n = 6). An ultrasound system with vendor‐specific software was used to determine fetal left ventricular (LV) and right ventricular (RV) geometry and function. Outcomes were compared with the remaining 25 gestational age‐matched ovine normoxic control pregnancies at 117 ± 1 (N1, n = 13), 124 ± 1 (N2, n = 5) and 133 ± 3 (N3, n = 7) dGA. Results: Compared to controls with expected fetal RV dominance in late gestation, hypoxic fetal sheep showed LV dominance with increasing duration of hypoxia, including statistically significant increases in mean ± SD LV/RV end‐diastolic area ratio (N1, 1.1 ± 0.2 vs H1, 1.3 ± 0.1; N2, 1.2 ± 0.4 vs H2, 1.7 ± 0.5; N3, 0.9 ± 0.1 vs H3, 1.4 ± 0.2), LV sphericity index (N3, 0.44 ± 0.04 vs H3, 0.54 ± 0.11) and LV/RV cardiac output ratio (N1, 0.55 ± 0.18 vs H1, 1.00 ± 0.31; N2, 0.80 ± 0.10 vs H2, 1.62 ± 0.59; N3, 0.74 ± 0.23 vs H3, 1.50 ± 0.58). The mean ± SD LV myocardial performance index was significantly greater in the hypoxic groups, signifying global myocardial dysfunction (N1, 0.45 ± 0.07 vs H1, 0.64 ± 0.07; N2, 0.40 ± 0.05 vs H2, 0.66 ± 0.07; N3, 0.36 ± 0.07 vs H3, 0.60 ± 0.10). While LV apical radial strain and LV apical systolic rotation were initially increased after 17 days of hypoxia, these indices were significantly reduced after 32 days of hypoxia (median LV apical radial strain: N1, 27% (interquartile range (IQR), 26–28%) vs H1, 24% (IQR, 21–26%); N2, 24% (IQR, 22–25%) vs H2, 70% (IQR, 66–79%); N3, 51% (IQR, 48–54%) vs H3, 29% (IQR, 27–32%); mean ± SD LV apical systolic rotation: N1, 7 ± 5° vs H1, 5 ± 3°; N2, 9 ± 1° vs H2, 14 ± 2°; N3, 15 ± 2° vs H3, 7 ± 2°). Hypoxic fetuses showed biventricular hypertrophy and evidence of biventricular diastolic dysfunction, with significant LV impairment presenting after 11 days of hypoxia (mean ± SD LV isovolumetric relaxation time (IVRT′) normalized by cardiac cycle (cc) length: N1, 0.10 ± 0.02 ms vs H1, 0.15 ± 0.02 ms; N2, 0.09 ± 0.01 ms vs H2, 0.14 ± 0.02 ms; N3, 0.08 ± 0.03 ms vs H3, 0.12 ± 0.02 ms), preceding RV impairment after 32 days of chronic hypoxia (mean ± SD RV‐IVRT′ normalized by cc length: N3, 0.08 ± 0.03 ms vs H3, 0.14 ± 0.03 ms). Conclusions: Progressive fetal hypoxia in sheep leads to profound changes in fetal cardiac structure and function, resulting from a switch to LV dominance triggered by fetal brain sparing. The findings also indicate that fetal cardiac compensatory reserves become exhausted with progressive hypoxia. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
- Open Access
- 13 May 2025
- Published by MDPI AG in Journal of Developmental Biology
- Vol. 13 (2) , 17
In Vitro Embryo Culture Impacts Heart Mitochondria in Male Adolescent Sheep
Assisted reproductive technology (ART)such as in vitro embryo culture (IVC), is widely used in human infertility treatments; however, its long-term effects on the cardiac health of offspring remain unclear. This study aimed to determine whether the effects of IVC on cardiac metabolism and associated signaling pathways persist after birth into adolescence. Embryos were either transferred to an intermediate ewe (ET) or cultured in vitro in the absence (IVC) or presence of human serum (IVCHS) with methionine supplementation (IVCHS+M) for 6 days after mating. Naturally mated (NM) ewes were used as controls. Protein expression and hormone concentrations in the left ventricle (LV) were analyzed using Western blot and LC-MS/MS analyses, respectively. IVC was associated with sex-specific alterations in cardiac mitochondria, with males exhibiting reduced mitochondrial abundance. Cardiac protein expression of oxidative phosphorylation (OXPHOS) complexes 1 and 4 was reduced by IVC. Additionally, IVC reduced protein expression of PDK-4 and Mn-SOD in the IVCHS+M group, which may impact energy efficiency and defense against oxidative stress. These changes may predispose IVC offspring to cardiac oxidative stress and mitochondrial dysfunction, particularly in males. This study provides insights into the sex-dependent effects of IVC on cardiac health, emphasizing the importance of evaluating long-term cardiovascular risks associated with IVC protocols.
- 13 May 2025
- Published by MDPI AG in Journal of Developmental Biology
- Vol. 13 (2) , 17
Open AccessIn Vitro Embryo Culture Impacts Heart Mitochondria in Male Adolescent Sheep
Assisted reproductive technology (ART)such as in vitro embryo culture (IVC), is widely used in human infertility treatments; however, its long-term effects on the cardiac health of offspring remain unclear. This study aimed to determine whether the effects of IVC on cardiac metabolism and associated signaling pathways persist after birth into adolescence. Embryos were either transferred to an intermediate ewe (ET) or cultured in vitro in the absence (IVC) or presence of human serum (IVCHS) with methionine supplementation (IVCHS+M) for 6 days after mating. Naturally mated (NM) ewes were used as controls. Protein expression and hormone concentrations in the left ventricle (LV) were analyzed using Western blot and LC-MS/MS analyses, respectively. IVC was associated with sex-specific alterations in cardiac mitochondria, with males exhibiting reduced mitochondrial abundance. Cardiac protein expression of oxidative phosphorylation (OXPHOS) complexes 1 and 4 was reduced by IVC. Additionally, IVC reduced protein expression of PDK-4 and Mn-SOD in the IVCHS+M group, which may impact energy efficiency and defense against oxidative stress. These changes may predispose IVC offspring to cardiac oxidative stress and mitochondrial dysfunction, particularly in males. This study provides insights into the sex-dependent effects of IVC on cardiac health, emphasizing the importance of evaluating long-term cardiovascular risks associated with IVC protocols.
- Open Access
- 22 February 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (3) , 285
Maternal MitoQ Treatment Is Protective Against Programmed Alterations in CYP Activity Due to Antenatal Dexamethasone
Background/Objectives: In pregnancy threatened by preterm birth, antenatal corticosteroids (ACS) are administered to accelerate fetal lung maturation. However, they have side effects, including the production of reactive oxygen species that can impact cytochrome P450 (CYP) activity. We hypothesised that antioxidants could protect a fetus treated with ACS during gestation and prevent the programming of altered hepatic CYP activity in the offspring. The primary outcome of our study was the impact of different maternal treatments on the activity of hepatic drug-metabolising enzymes in offspring. Methods: At 100 ± 1 days gestational age (dGA, term = 147 dGA), 73 ewes were randomly allocated to the following: saline (5 mL IV daily 105–137 ± 2 dGA, n = 17), ACS (Dexamethasone (Dex); 12 mg IM at 115 and 116 dGA; n = 25), MitoQ (6 mg/kg MS010 IV, daily bolus 105–137 ± 2 dGA; n = 17) or Dex and MitoQ (Dex+MitoQ; n = 14). CYP activity and protein abundance were assessed using functional assays and Western blot. Results: Dex decreased the hepatic activity of fetal CYP3A (−56%, PDex = 0.0322), and 9 mo lamb CYP1A2 (−22%, PDex = 0.0003), CYP2B6 (−36%, PDex = 0.0234), CYP2C8 (−34%, PDex = 0.0493) and CYP2E1 (−57%, PDex = 0.0009). For all, except CYP1A2, activity returned to control levels with Dex+MitoQ in 9 mo lambs. In 9 mo lambs, MitoQ alone increased activity of CYP2B6 (+16%, PMitoQ = 0.0011) and CYP3A (midazolam, +25%, PMitoQ = 0.0162) and increased CAT expression (PMitoQ = 0.0171). Dex+MitoQ increased CYP3A4/5 activity (testosterone, +65%, PIntx < 0.0003), decreased CYP1A2 activity (−14%, PIntx = 0.0036) and decreased mitochondrial abundance (PIntx = 0.0051). All treatments decreased fetal hepatic DRP1, a regulator of mitochondrial fission (PDex = 0.0055, PMitoQ = 0.0006 and PIntx = 0.0034). Conclusions: Antenatal Dex reduced activity of only one CYP in the fetus but programmed the reduced activity of several hepatic CYPs in young adult offspring, and this effect was ameliorated by combination with MitoQ.
- 22 February 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (3) , 285
Open AccessMaternal MitoQ Treatment Is Protective Against Programmed Alterations in CYP Activity Due to Antenatal Dexamethasone
Background/Objectives: In pregnancy threatened by preterm birth, antenatal corticosteroids (ACS) are administered to accelerate fetal lung maturation. However, they have side effects, including the production of reactive oxygen species that can impact cytochrome P450 (CYP) activity. We hypothesised that antioxidants could protect a fetus treated with ACS during gestation and prevent the programming of altered hepatic CYP activity in the offspring. The primary outcome of our study was the impact of different maternal treatments on the activity of hepatic drug-metabolising enzymes in offspring. Methods: At 100 ± 1 days gestational age (dGA, term = 147 dGA), 73 ewes were randomly allocated to the following: saline (5 mL IV daily 105–137 ± 2 dGA, n = 17), ACS (Dexamethasone (Dex); 12 mg IM at 115 and 116 dGA; n = 25), MitoQ (6 mg/kg MS010 IV, daily bolus 105–137 ± 2 dGA; n = 17) or Dex and MitoQ (Dex+MitoQ; n = 14). CYP activity and protein abundance were assessed using functional assays and Western blot. Results: Dex decreased the hepatic activity of fetal CYP3A (−56%, PDex = 0.0322), and 9 mo lamb CYP1A2 (−22%, PDex = 0.0003), CYP2B6 (−36%, PDex = 0.0234), CYP2C8 (−34%, PDex = 0.0493) and CYP2E1 (−57%, PDex = 0.0009). For all, except CYP1A2, activity returned to control levels with Dex+MitoQ in 9 mo lambs. In 9 mo lambs, MitoQ alone increased activity of CYP2B6 (+16%, PMitoQ = 0.0011) and CYP3A (midazolam, +25%, PMitoQ = 0.0162) and increased CAT expression (PMitoQ = 0.0171). Dex+MitoQ increased CYP3A4/5 activity (testosterone, +65%, PIntx < 0.0003), decreased CYP1A2 activity (−14%, PIntx = 0.0036) and decreased mitochondrial abundance (PIntx = 0.0051). All treatments decreased fetal hepatic DRP1, a regulator of mitochondrial fission (PDex = 0.0055, PMitoQ = 0.0006 and PIntx = 0.0034). Conclusions: Antenatal Dex reduced activity of only one CYP in the fetus but programmed the reduced activity of several hepatic CYPs in young adult offspring, and this effect was ameliorated by combination with MitoQ.
- Open Access
- 8 November 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (22) , 7034
The Challenge of Weight Stigma for Women in the Preconception Period: Workshop Recommendations for Action from the 5th European Conference on Preconception Health and Care
Weight stigma is a well-recognised public health issue affecting many members of society including women during the preconception period. The impacts of preconception weight stigma on women are significant and may result in decreased access to and uptake of healthcare, and mental health concerns. The consequences of this weight stigma may translate to negative maternal outcomes and even intergenerational effects on the child. Eliminating weight stigma is therefore imperative. The aim of this paper is to report recommendations to reduce weight stigma for preconception women produced at a workshop with clinical and academic experts on preconception health and weight stigma at the 5th European Conference on Preconception Health and Care. The recommendations are related to two key areas: general societal recommendations prompting all people to acknowledge and adjust our attitudes towards larger-bodied people; and healthcare-specific recommendations imploring clinicians to upskill themselves to reduce weight stigma in practice. We therefore call for urgent approaches to address societal weight-stigmatising attitudes and norms related to both the general population and preconception women, while providing professional development opportunities for healthcare professionals relating to weight stigma. Eliminating weight stigma for preconception women may have positive impacts on the outcomes for mothers and children during pregnancy and beyond.
- 8 November 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (22) , 7034
Open AccessThe Challenge of Weight Stigma for Women in the Preconception Period: Workshop Recommendations for Action from the 5th European Conference on Preconception Health and Care
Weight stigma is a well-recognised public health issue affecting many members of society including women during the preconception period. The impacts of preconception weight stigma on women are significant and may result in decreased access to and uptake of healthcare, and mental health concerns. The consequences of this weight stigma may translate to negative maternal outcomes and even intergenerational effects on the child. Eliminating weight stigma is therefore imperative. The aim of this paper is to report recommendations to reduce weight stigma for preconception women produced at a workshop with clinical and academic experts on preconception health and weight stigma at the 5th European Conference on Preconception Health and Care. The recommendations are related to two key areas: general societal recommendations prompting all people to acknowledge and adjust our attitudes towards larger-bodied people; and healthcare-specific recommendations imploring clinicians to upskill themselves to reduce weight stigma in practice. We therefore call for urgent approaches to address societal weight-stigmatising attitudes and norms related to both the general population and preconception women, while providing professional development opportunities for healthcare professionals relating to weight stigma. Eliminating weight stigma for preconception women may have positive impacts on the outcomes for mothers and children during pregnancy and beyond.
- Open Access
- 21 August 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (34) , eabb1929
Translatable mitochondria-targeted protection against programmed cardiovascular dysfunction
Mitochondrial therapy may cure hypertension in adult offspring of complicated pregnancies.
- 21 August 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (34) , eabb1929
Open AccessTranslatable mitochondria-targeted protection against programmed cardiovascular dysfunction
Mitochondrial therapy may cure hypertension in adult offspring of complicated pregnancies.
- Open Access
- 1 May 2019
- Published by The Royal Society in Journal of The Royal Society Interface
- Vol. 16 (154) , 20190013
Maternal and fetal cardiometabolic recovery following ultrasound-guided high-intensity focused ultrasound placental vascular occlusion
High-intensity focused ultrasound (HIFU) is a non-invasive method of selective placental vascular occlusion, providing a potential therapy for conditions such as twin–twin transfusion syndrome. In order to translate this technique into human studies, evidence of prolonged fetal recovery and maintenance of a healthy fetal physiology following exposure to HIFU is essential. At 116 ± 2 days gestation, 12 pregnant ewes were assigned to control ( n = 6) or HIFU vascular occlusion ( n = 6) groups and anaesthetized. Placental blood vessels were identified using colour Doppler ultrasound; HIFU-mediated vascular occlusion was performed through intact maternal skin (1.66 MHz, 5 s duration, in situ I SPTA 1.8–3.9 kW cm −2 ). Unidentifiable colour Doppler signals in targeted vessels following HIFU exposure denoted successful occlusion. Ewes and fetuses were then surgically instrumented with vascular catheters and transonic flow probes and recovered from anaesthesia. A custom-made wireless data acquisition system, which records continuous maternal and fetal cardiovascular data, and daily blood sampling were used to assess wellbeing for 20 days, followed by post-mortem examination. Based on a comparison of pre- and post-treatment colour Doppler imaging, 100% (36/36) of placental vessels were occluded following HIFU, and occlusion persisted for 20 days. All fetuses survived. No differences in maternal or fetal blood pressure, heart rate, heart rate variability, metabolic status or oxygenation were observed between treatment groups. There was evidence of normal fetal maturation and no evidence of chronic fetal stress. There were no maternal injuries and no placental vascular haemorrhage. There was both a uterine and fetal burn, which did not result in any obstetric or fetal complications. This study demonstrates normal long-term recovery of fetal sheep from exposure to HIFU-mediated placental vascular occlusion and underlines the potential of HIFU as a potential non-invasive therapy in human pregnancy.
- 1 May 2019
- Published by The Royal Society in Journal of The Royal Society Interface
- Vol. 16 (154) , 20190013
Open AccessMaternal and fetal cardiometabolic recovery following ultrasound-guided high-intensity focused ultrasound placental vascular occlusion
High-intensity focused ultrasound (HIFU) is a non-invasive method of selective placental vascular occlusion, providing a potential therapy for conditions such as twin–twin transfusion syndrome. In order to translate this technique into human studies, evidence of prolonged fetal recovery and maintenance of a healthy fetal physiology following exposure to HIFU is essential. At 116 ± 2 days gestation, 12 pregnant ewes were assigned to control ( n = 6) or HIFU vascular occlusion ( n = 6) groups and anaesthetized. Placental blood vessels were identified using colour Doppler ultrasound; HIFU-mediated vascular occlusion was performed through intact maternal skin (1.66 MHz, 5 s duration, in situ I SPTA 1.8–3.9 kW cm −2 ). Unidentifiable colour Doppler signals in targeted vessels following HIFU exposure denoted successful occlusion. Ewes and fetuses were then surgically instrumented with vascular catheters and transonic flow probes and recovered from anaesthesia. A custom-made wireless data acquisition system, which records continuous maternal and fetal cardiovascular data, and daily blood sampling were used to assess wellbeing for 20 days, followed by post-mortem examination. Based on a comparison of pre- and post-treatment colour Doppler imaging, 100% (36/36) of placental vessels were occluded following HIFU, and occlusion persisted for 20 days. All fetuses survived. No differences in maternal or fetal blood pressure, heart rate, heart rate variability, metabolic status or oxygenation were observed between treatment groups. There was evidence of normal fetal maturation and no evidence of chronic fetal stress. There were no maternal injuries and no placental vascular haemorrhage. There was both a uterine and fetal burn, which did not result in any obstetric or fetal complications. This study demonstrates normal long-term recovery of fetal sheep from exposure to HIFU-mediated placental vascular occlusion and underlines the potential of HIFU as a potential non-invasive therapy in human pregnancy.
- 30 May 2018
- Published by Wiley in The Journal of Physiology
- Vol. 596 (23) , 5535-5569
Guinea pig models for translation of the developmental origins of health and disease hypothesis into the clinic
Over 30 years ago Professor David Barker first proposed the theory that events in early life could explain an individual's risk of non‐communicable disease in later life: the developmental origins of health and disease (DOHaD) hypothesis. During the 1990s the validity of the DOHaD hypothesis was extensively tested in a number of human populations and the mechanisms underpinning it characterised in a range of experimental animal models. Over the past decade, researchers have sought to use this mechanistic understanding of DOHaD to develop therapeutic interventions during pregnancy and early life to improve adult health. A variety of animal models have been used to develop and evaluate interventions, each with strengths and limitations. It is becoming apparent that effective translational research requires that the animal paradigm selected mirrors the tempo of human fetal growth and development as closely as possible so that the effect of a perinatal insult and/or therapeutic intervention can be fully assessed. The guinea pig is one such animal model that over the past two decades has demonstrated itself to be a very useful platform for these important reproductive studies. This review highlights similarities in thein uterodevelopment between humans and guinea pigs, the strengths and limitations of the guinea pig as an experimental model of DOHaD and the guinea pig's potential to enhance clinical therapeutic innovation to improve human health. image
- 30 May 2018
- Published by Wiley in The Journal of Physiology
- Vol. 596 (23) , 5535-5569
Guinea pig models for translation of the developmental origins of health and disease hypothesis into the clinic
Over 30 years ago Professor David Barker first proposed the theory that events in early life could explain an individual's risk of non‐communicable disease in later life: the developmental origins of health and disease (DOHaD) hypothesis. During the 1990s the validity of the DOHaD hypothesis was extensively tested in a number of human populations and the mechanisms underpinning it characterised in a range of experimental animal models. Over the past decade, researchers have sought to use this mechanistic understanding of DOHaD to develop therapeutic interventions during pregnancy and early life to improve adult health. A variety of animal models have been used to develop and evaluate interventions, each with strengths and limitations. It is becoming apparent that effective translational research requires that the animal paradigm selected mirrors the tempo of human fetal growth and development as closely as possible so that the effect of a perinatal insult and/or therapeutic intervention can be fully assessed. The guinea pig is one such animal model that over the past two decades has demonstrated itself to be a very useful platform for these important reproductive studies. This review highlights similarities in thein uterodevelopment between humans and guinea pigs, the strengths and limitations of the guinea pig as an experimental model of DOHaD and the guinea pig's potential to enhance clinical therapeutic innovation to improve human health. image
- Open Access
- 29 April 2018
- Published by Wiley in The Journal of Physiology
- Vol. 596 (23) , 6105-6119
Altered autonomic control of heart rate variability in the chronically hypoxic fetus
Key points: Fetal heart rate variability (FHRV) has long been recognised as a powerful predictor of fetal wellbeing, and a decrease in FHRV is associated with fetal compromise. However, the mechanisms by which FHRV is reduced in the chronically hypoxic fetus have yet to be established. The sympathetic and parasympathetic influences on heart rate mature at different rates throughout fetal life, and can be assessed by time domain and power spectral analysis of FHRV. In this study of chronically instrumented fetal sheep in late gestation, we analysed FHRV daily over a 16 day period towards term, and compared changes between fetuses of control and chronically hypoxic pregnancy. We show that FHRV in sheep is reduced by chronic hypoxia, predominantly due to dysregulation of the sympathetic control of the fetal heart rate. This presents a potential mechanism by which a reduction in indices of FHRV predicts fetuses at increased risk of neonatal morbidity and mortality in humans. Reduction in overall FHRV may therefore provide a biomarker that autonomic dysregulation of fetal heart rate control has taken place in a fetus where uteroplacental dysfunction is suspected. Although fetal heart rate variability (FHRV) has long been recognised as a powerful predictor of fetal wellbeing, the mechanisms by which it is reduced in the chronically hypoxic fetus have yet to be established. In particular, the physiological mechanism underlying the reduction of short term variation (STV) in fetal compromise remains unclear. In this study, we present a longitudinal study of the development of autonomic control of FHRV, assessed by indirect indices, time domain and power spectral analysis, in normoxic and chronically hypoxic, chronically catheterised, singleton fetal sheep over the last third of gestation. We used isobaric chambers able to maintain pregnant sheep for prolonged periods in hypoxic conditions (stable fetal femoral arterial 10–12 mmHg), and a customised wireless data acquisition system to record beat‐to‐beat variation in the fetal heart rate. We determined in vivo longitudinal changes in overall FHRV and the sympathetic and parasympathetic contribution to FHRV in hypoxic (n = 6) and normoxic (n = 6) ovine fetuses with advancing gestational age. Normoxic fetuses show gestational age‐related increases in overall indices of FHRV, and in the sympathetic nervous system contribution to FHRV (P < 0.001). Conversely, gestational age‐related increases in overall FHRV were impaired by exposure to chronic hypoxia, and there was evidence of suppression of the sympathetic nervous system control of FHRV after 72 h of exposure to hypoxia (P < 0.001). This demonstrates that exposure to late gestation isolated chronic fetal hypoxia has the potential to alter the development of the autonomic nervous system control of FHRV in sheep. This presents a potential mechanism by which a reduction in indices of FHRV in human fetuses affected by uteroplacental dysfunction can predict fetuses at increased risk.
- 29 April 2018
- Published by Wiley in The Journal of Physiology
- Vol. 596 (23) , 6105-6119
Open AccessAltered autonomic control of heart rate variability in the chronically hypoxic fetus
Key points: Fetal heart rate variability (FHRV) has long been recognised as a powerful predictor of fetal wellbeing, and a decrease in FHRV is associated with fetal compromise. However, the mechanisms by which FHRV is reduced in the chronically hypoxic fetus have yet to be established. The sympathetic and parasympathetic influences on heart rate mature at different rates throughout fetal life, and can be assessed by time domain and power spectral analysis of FHRV. In this study of chronically instrumented fetal sheep in late gestation, we analysed FHRV daily over a 16 day period towards term, and compared changes between fetuses of control and chronically hypoxic pregnancy. We show that FHRV in sheep is reduced by chronic hypoxia, predominantly due to dysregulation of the sympathetic control of the fetal heart rate. This presents a potential mechanism by which a reduction in indices of FHRV predicts fetuses at increased risk of neonatal morbidity and mortality in humans. Reduction in overall FHRV may therefore provide a biomarker that autonomic dysregulation of fetal heart rate control has taken place in a fetus where uteroplacental dysfunction is suspected. Although fetal heart rate variability (FHRV) has long been recognised as a powerful predictor of fetal wellbeing, the mechanisms by which it is reduced in the chronically hypoxic fetus have yet to be established. In particular, the physiological mechanism underlying the reduction of short term variation (STV) in fetal compromise remains unclear. In this study, we present a longitudinal study of the development of autonomic control of FHRV, assessed by indirect indices, time domain and power spectral analysis, in normoxic and chronically hypoxic, chronically catheterised, singleton fetal sheep over the last third of gestation. We used isobaric chambers able to maintain pregnant sheep for prolonged periods in hypoxic conditions (stable fetal femoral arterial 10–12 mmHg), and a customised wireless data acquisition system to record beat‐to‐beat variation in the fetal heart rate. We determined in vivo longitudinal changes in overall FHRV and the sympathetic and parasympathetic contribution to FHRV in hypoxic (n = 6) and normoxic (n = 6) ovine fetuses with advancing gestational age. Normoxic fetuses show gestational age‐related increases in overall indices of FHRV, and in the sympathetic nervous system contribution to FHRV (P < 0.001). Conversely, gestational age‐related increases in overall FHRV were impaired by exposure to chronic hypoxia, and there was evidence of suppression of the sympathetic nervous system control of FHRV after 72 h of exposure to hypoxia (P < 0.001). This demonstrates that exposure to late gestation isolated chronic fetal hypoxia has the potential to alter the development of the autonomic nervous system control of FHRV in sheep. This presents a potential mechanism by which a reduction in indices of FHRV in human fetuses affected by uteroplacental dysfunction can predict fetuses at increased risk.